Quantitative SPECT/CT Imaging of 177Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy

被引：0
|
作者：
J. C. Sanders
T. Kuwert
J. Hornegger
P. Ritt
机构：
[1] University of Erlangen-Nuremberg,Pattern Recognition Lab, Department of Computer Science
[2] University of Erlangen-Nuremberg,Clinic of Nuclear Medicine, University Hospital Erlangen
来源：
Molecular Imaging and Biology | 2015年 / 17卷
关键词：
Quantitative SPECT; [; Lu]DOTATATE; Peptide receptor radionuclide therapy; Dosimetry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：585 / 593
页数：8
相关论文
共 50 条
  • [41] Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
    del Olmo-Garcia, Maria I.
    Prado-Wohlwend, Stefan
    Bello, Pilar
    Segura, Angel
    Merino-Torres, Juan F.
    CANCERS, 2022, 14 (03)
  • [42] Characterization of Noise and Resolution for Quantitative 177Lu SPECT/CT with xSPECT Quant
    Tran-Gia, Johannes
    Lassmann, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (01) : 50 - 59
  • [43] Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors A Meta-analysis
    Saravana-Bawan, Bianka
    Bajwa, Amandeep
    Paterson, John
    McEwan, Alexander J. B.
    McMullen, Todd P. W.
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 719 - 727
  • [44] Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy
    Abbott, Amanda
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2018, 46 (03) : 245 - 246
  • [45] In vivo quantification of 177Lu with planar whole-body and SPECT/CT gamma camera imaging
    Bailey D.L.
    Hennessy T.M.
    Willowson K.P.
    Henry E.C.
    Chan D.L.H.
    Aslani A.
    Roach P.J.
    EJNMMI Physics, 2 (1) : 1 - 17
  • [46] 177Lu peptide receptor radionuclide therapy, availability, radioprotection, cost: comparison of two administration methods
    Herbaut, F.
    Boukhlef, S.
    Lheureux, N.
    Legrand, J.
    Dekyndt, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S211 - S212
  • [47] SPECT/CT calibration using clinical dosimetry workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with 177Lu-DOTATATE
    Mora Ramirez, E.
    Santoro, L.
    Trauchessec, D.
    Chouaf, S.
    Deshayes, E.
    Pouget, J.
    Kotzki, P.
    Bardies, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S809 - S810
  • [48] Prognostic value of post-therapy SPECT/CT imaging in patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy: results from 3 clinical trials
    Karri, Raghava
    Buteau, James
    Eifer, Michal
    Bollampally, Neeraja
    Bressel, Mathias
    Sandhu, Shahneen
    Hofman, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [49] In-vivo stability of 177Lu-DOTATATE during peptide receptor radionuclide therapy
    Wilking, H.
    Ilan, E.
    Sandstrom, M.
    Andersson, C.
    Ost, A.
    Velikyan, I.
    Fross-Baron, K.
    Sundin, A.
    Lubberink, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S592 - S592
  • [50] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
    Geenen, Lorain
    Nonnekens, Julie
    Konijnenberg, Mark
    Baatout, Sarah
    De Jong, Marion
    Aerts, An
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 102 : 1 - 11
12345